<DOC>
	<DOCNO>NCT02167113</DOCNO>
	<brief_summary>This non-interventional clinical study conduct prospectively collect serial plasma sample subject chronic HBV infection initiate antiviral therapy . These sample use estimate clinical utility endpoint Aptima HBV Quant assay , use aid management HBV-infected patient undergo HBV antiviral therapy .</brief_summary>
	<brief_title>Collection Samples Clinical Evaluation Aptima HBV ( Hepatitis B Virus ) Quant ( Quantification ) Assay</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>The subject chronically infect HBV.The subject treatment naïve initiate HBV antiviral therapy either entecavir tenofovir indicate FDA approve label The subject consider treatment naïve he/she &lt; 12 week oral antiviral therapy nucleoside nucleotide therapy The subject least 18 year age time enrollment Adequate medical record available collection protocoldefined demographic , baseline patient characteristic , medical history , virology specific laboratory result , information verify enrollment criterion The subject and/or legally authorize representative willing able provide consent prior provide specimen ( ) Subject one follow patient population : Acute HBV infection Patients HBV immune tolerant Human immunodeficiency virus ( HIV ) and/or hepatitis C virus ( HCV ) coinfection Solid organ bone marrow transplant recipient Renal failure dialysis Evidence history hepatic decompensation Evidence history hepatocellular carcinoma Underlying liver disease HBV Receiving chemotherapy , immunosuppressive agent Subject unsuitable study participation base Investigator 's decision ( eg , unlikely comply study visit schedule , significant medical complication ) Participating another investigational study Investigator believe might interfere subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>